Literature DB >> 22433346

Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries.

Najoua El Helali1, Yves Giovangrandi, Kathleen Guyot, Karine Chevet, Laurent Gutmann, Isabelle Durand-Zaleski.   

Abstract

OBJECTIVE: To estimate the cost and consequences of intrapartum polymerase chain reaction (PCR) screening on early-onset group B streptococcal (GBS) disease compared with the antenatal lower vagina culture screening recommended in France.
METHODS: This was a single-institution study comparing the intrapartum PCR screening strategy implemented in 2010 with antenatal culture strategy in place in 2009. Early-onset GBS disease in newborns was monitored exhaustively. We estimated direct costs, including screening test costs and hospital costs, for deliveries of healthy newborns compared with those infected with GBS. Costs in 2009 and 2010 were compared on an intention-to-treat basis.
RESULTS: Term deliveries were 2,761 and 2,814 in 2009 and 2010, respectively. Among the screened mothers, the vaginal GBS colonization rate was 11.7% based on antenatal GBS culture screening in 2009 compared with 16.7% in 2010 using the intrapartum PCR testing. The overall probabilities of neonatal GBS disease were 0.9% compared with 0.5%, and the average total cost per delivery was $1,759±1,209 in 2009 compared with $1,754±842 in 2010 (P=.9) in antenatal and intrapartum screening strategies, respectively. The number and severity of cases of early-onset GBS disease and the resulting hospital costs were higher in 2009.
CONCLUSION: Polymerase chain reaction intrapartum screening strategy was cost-neutral when compared with the 2009 antenatal lower vagina culture screening, with a significant decrease in early-onset GBS disease.

Entities:  

Mesh:

Year:  2012        PMID: 22433346     DOI: 10.1097/AOG.0b013e31824b1461

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  12 in total

Review 1.  Molecular-based screening for perinatal group B streptococcal infection: implications for prevention and therapy.

Authors:  Stéphane Emonet; Jacques Schrenzel; Begoña Martinez de Tejada
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

2.  Intrapartum group B Streptococcus screening in the labor ward by Xpert® GBS real-time PCR.

Authors:  C Plainvert; F El Alaoui; A Tazi; C Joubrel; O Anselem; M Ballon; A Frigo; C Branger; L Mandelbrot; F Goffinet; C Poyart
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-29       Impact factor: 3.267

3.  Streptococcus agalactiae Strains with Chromosomal Deletions Evade Detection with Molecular Methods.

Authors:  Isabella A Tickler; Fred C Tenover; Scott Dewell; Victoria M Le; Rachel N Blackman; Richard V Goering; Amy E Rogers; Heather Piwonka; Brittney D Jung-Hynes; Derrick J Chen; Michael J Loeffelholz; Devasena Gnanashanmugam; Ellen Jo Baron
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Evaluation of the Cepheid Xpert GBS assay for rapid detection of group B Streptococci in amniotic fluids from pregnant women with premature rupture of membranes.

Authors:  Nadege Bourgeois-Nicolaos; Anne-Gael Cordier; Christelle Guillet-Caruba; François Casanova; Alexandra Benachi; Florence Doucet-Populaire
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

5.  Successful off-label use of the Cepheid Xpert GBS in a late-onset neonatal meningitis by Streptococcus agalactiae.

Authors:  Vincenzo Savini; Roberta Marrollo; Eleonora Coclite; Paola Fusilli; Carmine D'Incecco; Paolo Fazii
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Evaluation of the new brilliance GBS chromogenic medium for screening of Streptococcus agalactiae vaginal colonization in pregnant women.

Authors:  Paul O Verhoeven; Pauline Noyel; Julie Bonneau; Anne Carricajo; Nathalie Fonsale; Alain Ros; Bruno Pozzetto; Florence Grattard
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

7.  Multicenter clinical evaluation of the Xpert GBS LB assay for detection of group B Streptococcus in prenatal screening specimens.

Authors:  Blake W Buchan; Matthew L Faron; DeAnna Fuller; Thomas E Davis; Donna Mayne; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

8.  Comparison of qPCR and culture methods for group B Streptococcus colonization detection in pregnant women: evaluation of a new qPCR assay.

Authors:  J A Carrillo-Ávila; J Gutiérrez-Fernández; A I González-Espín; E García-Triviño; L G Giménez-Lirola
Journal:  BMC Infect Dis       Date:  2018-07-05       Impact factor: 3.090

Review 9.  Antibiotic use and misuse during pregnancy and delivery: benefits and risks.

Authors:  Begoña Martinez de Tejada
Journal:  Int J Environ Res Public Health       Date:  2014-08-07       Impact factor: 3.390

10.  Risk factors for group B streptococcal disease in neonates of mothers with negative antenatal testing.

Authors:  V Parente; R H Clark; L Ku; C Fennell; M Johnson; E Morris; A Romaine; U Utin; D K Benjamin; J A Messina; P B Smith; R G Greenberg
Journal:  J Perinatol       Date:  2016-11-17       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.